Our study demonstrated that SIX1, the well-known glycolytic and cell growth promoter, was a direct target of β-catenin to promote glucose metabolism in GC, and sf-RON can promote cell proliferation by increasing glucose metabolism via β-catenin/SIX1 signaling pathway. The gene discussed is SIX1; the disease is gastric cancer.